Janux Therapeutics Inc (JANX)

Janux Therapeutics Inc Stock Analysis & Ratings

JANX Stock Chart & Stats

Day’s Range$11.07 - $11.07
52-Week Range$9.39 - $37.99
Previous Close$10.91
Average Volume (3M)79.45K
Market Cap$447.52M
P/E Ratio-10.3
Next EarningsAug 09, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score4
EPS (TTM)-1.06



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.


Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was Janux Therapeutics Inc’s price range in the past 12 months?
Janux Therapeutics Inc lowest stock price was $9.39 and its highest was $37.99 in the past 12 months.
    What is Janux Therapeutics Inc’s market cap?
    Janux Therapeutics Inc’s market cap is $447.52M.
      What is Janux Therapeutics Inc’s price target?
      The average price target for Janux Therapeutics Inc is $32.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $35.00 ,the lowest forecast is $30.00. The average price target represents 202.33% Increase from the current price of $10.75.
        What do analysts say about Janux Therapeutics Inc?
        Janux Therapeutics Inc’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
          When is Janux Therapeutics Inc’s upcoming earnings report date?
          Janux Therapeutics Inc’s upcoming earnings report date is Aug 09, 2022 which is in 74 days.
            How were Janux Therapeutics Inc’s earnings last quarter?
            Janux Therapeutics Inc released its earnings results on May 10, 2022. The company reported -$0.32 earnings per share for the quarter, the consensus estimate of -$0.32 by $0.
              Is Janux Therapeutics Inc overvalued?
              According to Wall Street analysts Janux Therapeutics Inc’s price is currently Undervalued.
                Does Janux Therapeutics Inc pay dividends?
                Janux Therapeutics Inc does not currently pay dividends.
                What is Janux Therapeutics Inc’s EPS estimate?
                Janux Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Janux Therapeutics Inc have?
                Janux Therapeutics Inc has 41,630,000 shares outstanding.
                  What happened to Janux Therapeutics Inc’s price movement after its last earnings report?
                  Janux Therapeutics Inc reported an EPS of -$0.32 in its last earnings report, expectations of -$0.32. Following the earnings report the stock price went up 0.978%.
                    Which hedge fund is a major shareholder of Janux Therapeutics Inc?
                    Among the largest hedge funds holding Janux Therapeutics Inc’s share is RA Capital Management. It holds Janux Therapeutics Inc’s shares valued at 124M.


                      Janux Therapeutics Inc Stock Analysis

                      The Janux Therapeutics Inc stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Janux Therapeutics Inc

                      Janux Therapeutics Inc is an innovative biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to better treat patients suffering from cancer.

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis